Mitsubishi UFJ Asset Management Co. Ltd. Acquires New Holdings in Omnicell, Inc. $OMCL

Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Omnicell, Inc. (NASDAQ:OMCL – Free Report) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 24,140 shares of the company’s stock, valued at approximately $1,002,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in OMCL. Raymond James Financial Inc. acquired a new stake in shares of Omnicell in the second quarter worth $26,000. Versant Capital Management Inc boosted its holdings in shares of Omnicell by 38.7% during the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after buying an additional 294 shares during the period. Clearstead Advisors LLC grew its stake in Omnicell by 12,180.0% in the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after buying an additional 1,218 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in Omnicell in the 4th quarter valued at $58,000. Finally, Parkside Financial Bank & Trust lifted its position in Omnicell by 1,708.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock worth $61,000 after acquiring an additional 1,264 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Get Omnicell alerts:

Omnicell Trading Up 0.2%

Omnicell stock opened at $35.58 on Friday. The business has a 50 day moving average price of $40.38 and a two-hundred day moving average price of $39.68. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12 month low of $29.06 and a 12 month high of $55.00. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of 42.36, a price-to-earnings-growth ratio of 0.89 and a beta of 0.98.

Omnicell (NASDAQ:OMCL – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The company had revenue of $312.21 million during the quarter, compared to the consensus estimate of $310.21 million. During the same period last year, the firm earned $0.45 EPS. The firm’s revenue for the quarter was up 7.4% compared to the same quarter last year. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, equities analysts forecast that Omnicell, Inc. will post 1.41 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Craig Hallum restated a “buy” rating and set a $55.00 price target on shares of Omnicell in a report on Wednesday, April 29th. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Zacks Research cut Omnicell from a “hold” rating to a “strong sell” rating in a research report on Friday, August 7th. Weiss Ratings upgraded Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday. Finally, Wells Fargo & Company lowered their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.86.

Check Out Our Latest Analysis on Omnicell

About Omnicell

(Free Report)

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

Featured Articles

• Five stocks we like better than Omnicell
• 2 Biotech Stocks Shaping Up for Major Breakouts
• 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
• 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
• Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL – Free Report).

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.